VivoSeq
12

Pipeline Programs

0

Active Trials

5

Companies Involved

Thyroiditis is an emerging landscape with 12 programs across 5 companies. The most active players are Boehringer Ingelheim, Merck & Co., Dawnrays Pharmaceutical (Holdings) Limited.

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

92%

Small molecule

12 of 13 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Trial Status

9

clinical trials

Completed5 · 56%
Unknown status4 · 44%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)